Gyre Therapeutics (GYRE) Inventory Average (2024 - 2026)

Gyre Therapeutics (GYRE) has reported Inventory Average for 3 consecutive years, with $10.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory Average rose 51.41% year-over-year to $10.8 million; the TTM figure through Mar 2026 stood at $10.8 million (up 51.41% YoY), while the FY2025 annual figure was $8.3 million, up 55.47% from the prior year.
• Inventory Average rose to $10.8 million in Q1 2026 per GYRE's latest filing, from $9.5 million in the prior quarter.
• Across five years, Inventory Average topped out at $10.8 million in Q1 2026 and bottomed at $4.6 million in Q1 2024.
• Historically, Inventory Average has averaged $7.4 million across 3 years, with a median of $7.1 million in 2025.
• On a YoY basis, Inventory Average climbed as much as 58.3% in 2025 and fell as far as 47.45% in 2025.
• Gyre Therapeutics' Inventory Average stood at $6.4 million in 2024, then jumped by 49.61% to $9.5 million in 2025, then rose by 13.13% to $10.8 million in 2026.
• Business Quant data shows GYRE's Inventory Average at $10.8 million in Q1 2026, $9.5 million in Q4 2025, and $8.9 million in Q3 2025.